Insights
Keep up with the latest news, insights and events from Norstella and its market-leading brands
- Article
Why an AI-native biotech chose Norstella
Drug development has made huge scientific progress over the last decade. The way we run clinical development has changed far less. Timelines are still long. Costs are still high. And most of the risk is decided before a trial even begins—we just don’t treat it…
- Article
Wall Street Journal spotlights Norstella in post-pandemic vaccines feature
Norstella recently spoke with the Wall Street Journal’s Brian Gormley in a feature article: Biotech VC’s Vaccine Die-Hards. The piece explores how investment has pivoted away from vaccines, leaving a select group of committed developers to carry the flag. Strides made during the pandemic mean…
- Article
Rare … but actually not that rare
Rare Disease Day will be commemorated on 28 February this year, as it has been every year since 2008. Coordinated by EURORDIS-Rare Diseases Europe, the day will bring together over 70 national groups across 106 countries in over 600 events to raise awareness and drive…
- Article
Early oral GLP-1 uptake is half the story: Who is initiating reveals a bigger shift
In the first few weeks following the launch of oral semaglutide, early prescription activity answered a familiar question: Uptake was occurring and growing exponentially within a matter of weeks. But a more consequential signal emerged when looking beyond prescription counts to the patients themselves. After…
Work with us
Join our mission
We’re looking for agile, growth-oriented team players who are passionate about client success and helping clients bring life-saving therapies to market quicker—and help patients in need.
Get in touch
Let's connect
Have questions about Norstella or its brands? Or do you want to know more about how to solve your challenges at each stage of the drug life cycle?